🔴 Neurosense Therapeutics is trading 5.5% down; no direct announcement link identified

Neurosense Therapeutics is trading at $1.88, down 5.53% on November 2, 2026; no source directly linked the decline to the announcement.

• The company announced additional PrimeC biomarker data for its planned Canadian ALS submission.
• It moved the target filing from December 2026 to March 2027; Health Canada had no concerns with the revised timeline.
• Broader indices were rising, so the supplied context does not support a market-wide explanation.